NO175845B - - Google Patents
Download PDFInfo
- Publication number
- NO175845B NO175845B NO864682A NO864682A NO175845B NO 175845 B NO175845 B NO 175845B NO 864682 A NO864682 A NO 864682A NO 864682 A NO864682 A NO 864682A NO 175845 B NO175845 B NO 175845B
- Authority
- NO
- Norway
- Prior art keywords
- potassium
- phosphate
- mmol
- magnesium
- preparation
- Prior art date
Links
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 30
- 239000011591 potassium Substances 0.000 claims abstract description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 26
- 239000011777 magnesium Substances 0.000 claims abstract description 19
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 16
- 150000001720 carbohydrates Chemical class 0.000 claims description 11
- 235000014633 carbohydrates Nutrition 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 2
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims 1
- 235000005911 diet Nutrition 0.000 abstract description 16
- 230000037213 diet Effects 0.000 abstract description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 13
- 230000019522 cellular metabolic process Effects 0.000 abstract description 10
- 239000011780 sodium chloride Substances 0.000 abstract description 7
- 210000002700 urine Anatomy 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 5
- 150000003839 salts Chemical class 0.000 abstract description 5
- 235000019577 caloric intake Nutrition 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 description 19
- 239000010452 phosphate Substances 0.000 description 19
- 235000021317 phosphate Nutrition 0.000 description 19
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 16
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 description 13
- 239000011707 mineral Substances 0.000 description 13
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 12
- 229910001882 dioxygen Inorganic materials 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 235000010755 mineral Nutrition 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 10
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 9
- 230000029142 excretion Effects 0.000 description 8
- 239000001103 potassium chloride Substances 0.000 description 8
- 235000011164 potassium chloride Nutrition 0.000 description 8
- 235000011009 potassium phosphates Nutrition 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 229910000160 potassium phosphate Inorganic materials 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 6
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000015424 sodium Nutrition 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 5
- 235000001916 dieting Nutrition 0.000 description 5
- 230000037228 dieting effect Effects 0.000 description 5
- 229960002179 ephedrine Drugs 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- YQRTZUSEPDULET-UHFFFAOYSA-K magnesium;potassium;phosphate Chemical compound [Mg+2].[K+].[O-]P([O-])([O-])=O YQRTZUSEPDULET-UHFFFAOYSA-K 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 206010033307 Overweight Diseases 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940095884 glucophage Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000014659 low sodium diet Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 235000012015 potatoes Nutrition 0.000 description 3
- 235000015598 salt intake Nutrition 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000021045 dietary change Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- -1 ion chloride Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical class [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 230000000523 phosphaturic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- ZLMJMSJWJFRBEC-OUBTZVSYSA-N potassium-40 Chemical compound [40K] ZLMJMSJWJFRBEC-OUBTZVSYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Special Wing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Seasonings (AREA)
- Saccharide Compounds (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8505527A SE468074B (sv) | 1985-11-22 | 1985-11-22 | Preparat foer foerbaettring av den cellulaera metabolismen |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO864682D0 NO864682D0 (no) | 1986-11-21 |
| NO864682L NO864682L (no) | 1987-05-25 |
| NO175845B true NO175845B (fr) | 1994-09-12 |
| NO175845C NO175845C (no) | 1994-12-21 |
Family
ID=20362216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO864682A NO175845C (no) | 1985-11-22 | 1986-11-21 | Anvendelse av kalium-, magnesium- og fosfationer i slankepreparat |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0223762B1 (fr) |
| JP (1) | JPH07100660B2 (fr) |
| AT (1) | ATE74760T1 (fr) |
| AU (1) | AU592385B2 (fr) |
| CA (1) | CA1275927C (fr) |
| DE (2) | DE3684882D1 (fr) |
| DK (1) | DK164200C (fr) |
| FI (1) | FI864749A (fr) |
| NO (1) | NO175845C (fr) |
| SE (1) | SE468074B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207800B (en) * | 1990-05-10 | 1993-06-28 | Andras Sikter | Process for producing composition for improving condition and for treating different illnesses |
| US5639471A (en) * | 1995-06-06 | 1997-06-17 | Campbell Soup Company | Method for determining diet program effectiveness |
| DE19925483A1 (de) * | 1998-06-04 | 2000-02-03 | Ludwig Schwebel | Wirkstoff zur Behandlung der Zuckerkrankheit |
| GB9819530D0 (en) | 1998-09-09 | 1998-10-28 | Smithkline Beecham Plc | Novel compositions and use |
| US9585827B2 (en) * | 2000-01-21 | 2017-03-07 | The Procter & Gamble Company | Kits comprising a beverage composition and information for use |
| CN102949413B (zh) * | 2012-06-08 | 2014-12-03 | 辽宁海思科制药有限公司 | 一种转化糖电解质注射液的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1796976A (en) * | 1975-09-23 | 1978-04-06 | Johnson & Johnson | Electrolyte mixtures and drinks |
| US4322407A (en) * | 1978-12-11 | 1982-03-30 | Vitapharm Pharmaceutical Pty. Ltd. | Electrolyte drink |
-
1985
- 1985-11-22 SE SE8505527A patent/SE468074B/sv not_active Application Discontinuation
-
1986
- 1986-11-14 AU AU65133/86A patent/AU592385B2/en not_active Ceased
- 1986-11-18 AT AT86850396T patent/ATE74760T1/de not_active IP Right Cessation
- 1986-11-18 DE DE8686850396T patent/DE3684882D1/de not_active Expired - Fee Related
- 1986-11-18 JP JP61273068A patent/JPH07100660B2/ja not_active Expired - Lifetime
- 1986-11-18 DE DE198686850396T patent/DE223762T1/de active Pending
- 1986-11-18 EP EP86850396A patent/EP0223762B1/fr not_active Expired - Lifetime
- 1986-11-21 FI FI864749A patent/FI864749A/fi not_active Application Discontinuation
- 1986-11-21 CA CA000523514A patent/CA1275927C/fr not_active Expired - Fee Related
- 1986-11-21 NO NO864682A patent/NO175845C/no unknown
- 1986-11-21 DK DK560286A patent/DK164200C/da not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE8505527L (sv) | 1987-05-23 |
| AU6513386A (en) | 1987-05-28 |
| FI864749A0 (fi) | 1986-11-21 |
| SE8505527D0 (sv) | 1985-11-22 |
| CA1275927C (fr) | 1990-11-06 |
| NO864682L (no) | 1987-05-25 |
| DE3684882D1 (de) | 1992-05-21 |
| FI864749A (fi) | 1987-05-23 |
| DK560286A (da) | 1987-05-23 |
| SE468074B (sv) | 1992-11-02 |
| EP0223762B1 (fr) | 1992-04-15 |
| EP0223762A1 (fr) | 1987-05-27 |
| AU592385B2 (en) | 1990-01-11 |
| NO864682D0 (no) | 1986-11-21 |
| JPH07100660B2 (ja) | 1995-11-01 |
| NO175845C (no) | 1994-12-21 |
| ATE74760T1 (de) | 1992-05-15 |
| DK164200B (da) | 1992-05-25 |
| DK560286D0 (da) | 1986-11-21 |
| JPS62171654A (ja) | 1987-07-28 |
| DK164200C (da) | 1992-10-19 |
| DE223762T1 (de) | 1987-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Flatt | Use and storage of carbohydrate and fat | |
| US5925377A (en) | Dietary supplement composition | |
| Felig | Insulin is the mediator of feecling‐related thermogenesis: insulin resistance and/or deficiency results in a thermogenic defect which contributes to the pathogenesis of obesity | |
| JP2593882B2 (ja) | エネルギー補給用スポーツ飲料 | |
| Kempster et al. | Dietary factors in the management of Parkinson's disease | |
| US5484623A (en) | Dietary system high in oil intake for the treatment of obesity and for the lowering of saturated fats | |
| Landsberg | Obesity and hypertension: experimental data | |
| NO314824B1 (no) | Drikk og törr sammensetning | |
| Zinker | Nutrition and exercise in individuals with diabetes | |
| Harris | Feeding management of elite endurance horses | |
| NO175845B (fr) | ||
| Shetty | Chronic undernutrition and metabolic adaptation | |
| Voors | Does lithium depletion cause atherosclerotic heart-disease? | |
| Martin et al. | The regulation of body weight | |
| Wilson | Southwestern internal medicine conference: Treatment of obesity | |
| Leutholtz et al. | Optimizing nutrition for exercise and sport | |
| Brouns | Nutritional aspects of health and performance at lowland and altitude | |
| Katahn et al. | Obesity: a biobehavioral point of view | |
| Martin et al. | Glucose metabolism during physical exercise in patients with noninsulin-dependent (type II) diabetes | |
| US20120231098A1 (en) | Weight loss composition | |
| Lawrence | The Action of Insulin in Glycogen Formation and Its Therapeutic Application | |
| US20230023788A1 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
| Novials et al. | Adapting the Consumption of Carbohydrates for Diabetic Athletes | |
| Jung et al. | The Role of Dietary Essential Amino Acids in Muscle and Health | |
| Liao et al. | Cyclic Total Parenteral Nutrition Decreases Conjugated Bilirubin in Adult Patients with Parenteral Nutrition-Associated Liver Disease |